טוען...

The HB22.7–vcMMAE antibody–drug conjugate has efficacy against non-Hodgkin lymphoma mouse xenografts with minimal systemic toxicity

In this study, HB22.7, an anti-CD22 monoclonal antibody, was used for specific, targeted delivery of monomethyl auristatin E (MMAE) to non-Hodgkin lymphoma (NHL). MMAE was covalently coupled to HB22.7 through a valine–citrulline peptide linker (vc). Maleimide-functionalized vcMMAE (mal-vcMMAE) was r...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Cancer Immunol Immunother
Main Authors: Abuhay, Mastewal, Kato, Jason, Tuscano, Emily, Barisone, Gustavo A., Sidhu, Ranjit S., O’Donnell, Robert T., Tuscano, Joseph M.
פורמט: Artigo
שפה:Inglês
יצא לאור: Springer Berlin Heidelberg 2016
נושאים:
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC7643839/
https://ncbi.nlm.nih.gov/pubmed/27506529
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00262-016-1873-y
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!